AC
PACB icon

Athanor Capital’s Pacific Biosciences PACB Stock Holding History

Athanor Capital’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-94,172
Closed -$929K – 792
2020
Q3 		$929K Buy
94,172
+31,842
+51% +$183K 0.04% 250
2020
Q2 		$215K Buy
+62,330
New +$212K 0.01% 485

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Athanor Capital's PACB Position: Q4 2020 in Review

Athanor Capital sold out of Pacific Biosciences (PACB) in Q4 2020, closing a stake of 94,172 shares — an estimated $929K sold.

Athanor Capital first reported a position in PACB in Q2 2020 and held it in 2 quarters. The position peaked at $929K in Q3 2020. 210 funds tracked by Wall St. Rank hold PACB as of Q4 2020.

  • Athanor Capital reported no remaining Pacific Biosciences position as of Q4 2020 after selling out during the quarter.
  • Athanor Capital sold 94,172 Pacific Biosciences shares in Q4 2020, an estimated $929K.
  • Athanor Capital first reported a position in Pacific Biosciences in Q2 2020 and held it in 2 quarters.
  • Athanor Capital's Pacific Biosciences position peaked at $929K in Q3 2020.
  • 210 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2020.

Based on Athanor Capital's 13F filing for Q4 2020, filed 16 Feb 2021.